name
stringlengths 8
13
| light_chain_class
stringclasses 2
values | type
stringclasses 5
values | original_mab_isotype_or_format
stringclasses 17
values | clinical_status
stringclasses 3
values | phagec
bool 2
classes | year_name_proposed
int64 1.99k
2.01k
| metadata_notes
stringclasses 3
values | vh
stringlengths 112
130
| vl
stringlengths 104
113
| lc_class
stringclasses 2
values | source
stringclasses 3
values | source_detaileda
stringlengths 4
9
| disclaimers_and_known_issues
stringclasses 6
values | sequence_info_notes
stringclasses 1
value | hek_titer_mg_l
float64 6.58
277
| fab_tm_by_dsf_deg_c
float64 59.5
91.5
| sgac_sins_as100_nh4_2so4_mm
float64 0
1k
| hic_retention_time_min_a
float64 8.47
25
| smac_retention_time_min_a
float64 8.49
25
| slope_for_accelerated_stability
float64 -0.01
1.27
| poly_specificity_reagent_psr_smp_score_0_1
float64 0
0.81
| affinity_capture_self_interaction_nanoparticle_spectroscopy_ac_sins_delta_lambda_max_nm_average
float64 -1.08
29.9
| cic_retention_time_min
float64 8.26
13.5
| csi_bli_delta_response_nm
float64 -0.05
0.6
| elisa
float64 0.89
14.5
| bvp_elisa
float64 1.03
22.7
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
abituzumab
|
kappa
|
ZU
|
IgG2
|
Phase 2
| false | 2,013 |
a Made with human isotype
|
QVQLQQSGGELAKPGASVKVSCKASGYTFSSFWMHWVRQAPGQGLEWIGYINPRSGYTEYNEIFRDKATMTTDTSTSTAYMELSSLRSEDTAVYYCASFLGRGAMDYWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKLLIYYTSKIHSGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQGNTFPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL109
| null |
aPL and RL refer to WHO-INN publications for proposed and recommended lists
| 89.555458 | 75.5 | 900 | 9.227 | 8.725 | 0.05563 | 0.166666 | 1.458861 | 8.621 | 0 | 1.137375 | 2.720799 |
abrilumab
|
kappa
|
HU
|
IgG2
|
Phase 2
| false | 2,014 |
b Mixed chimeric, humanized LC and HC
|
QVQLVQSGAEVKKPGASVKVSCKVSGYTLSDLSIHWVRQAPGKGLEWMGGFDPQDGETIYAQKFQGRVTMTEDTSTDTAYMELSSLKSEDTAVYYCATGSSSSWFDPWGQGTLVTVSS
|
DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFANYYCQQANSFPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 100.223196 | 71 | 900 | 9.413 | 8.699 | 0.02829 | 0 | -0.928526 | 8.384 | -0.02 | 1.124624 | 1.818303 |
adalimumab
|
kappa
|
HU
|
IgG1
|
Approved
| true | 1,999 |
c Most as those molecules labeled Yes in the phage column were discovered and or optimized by phage display. A small number of these were optimized by fragment-based phage techniques not involving display.
|
EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIK
|
kappa
|
PDB
|
4NYL
| null | null | 134.928638 | 71 | 900 | 8.816 | 8.672 | 0.05069 | 0 | 1.062328 | 8.865 | -0.01 | 1.075515 | 1.488186 |
alemtuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,000 | null |
QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIK
|
kappa
|
PDB
|
1BEY
| null | null | 144.653543 | 74.5 | 1,000 | 8.769 | 8.672 | 0.06431 | 0 | -0.789199 | 8.514 | -0.02 | 1.161491 | 1.464226 |
alirocumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,012 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS
|
DIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 69.232345 | 71.5 | 900 | 9.036 | 8.681 | 0.0292 | 0 | 1.230511 | 8.757 | -0.01 | 1.196224 | 2.1797 |
anifrolumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false | 2,013 | null |
EVQLVQSGAEVKKPGESLKISCKGSGYIFTNYWIAWVRQMPGKGLESMGIIYPGDSDIRYSPSFQGQVTISADKSITTAYLQWSSLKASDTAMYYCARHDIEGFDYWGRGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFFAWYQQKPGQAPRLLIYGASSRATGIPDRLSGSGSGTDFTLTITRLEPEDFAVYYCQQYDSSAITFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 82.046821 | 62.5 | 700 | 8.799 | 8.629 | 0.0708 | 0 | -0.561397 | 8.489 | -0.02 | 1.15745 | 1.623295 |
atezolizumab
|
kappa
|
ZU
|
IgG1-no-glyco
|
Approved
| true | 2,014 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL112
| null | null | 164.085804 | 73.5 | 300 | 13.353 | 19.283 | 0.0556 | 0.065812 | 14.971122 | 10.76 | 0.06 | 1.294746 | 6.197378 |
bapineuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 2,005 | null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAPGKGLEWVASIRSGGGRTYYSDNVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRYDHYSGSSDYWGQGTLVTVSS
|
DVVMTQSPLSLPVTPGEPASISCKSSQSLLDSDGKTYLNWLLQKPGQSPQRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US7582733
|
Conflicting literature sequences in FR3 of VH - AKNTLYLQMNSLRAEDTAV vs. AKNSLYLQMNSLRAEDTAL
| null | 151.09165 | 73 | 1,000 | 8.855 | 8.655 | 0.07017 | 0 | -0.734256 | 8.619 | 0.06 | 1.20895 | 3.548752 |
basiliximab
|
kappa
|
XI
|
IgG1
|
Approved
| false | 1,996 | null |
QVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS
|
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK
|
kappa
|
PDB
|
1MIM
| null | null | 107.461588 | 60.5 | 0 | 9.578 | 8.576 | 0.0476 | 0.397164 | 28.757059 | 9.449 | 0 | 1.201328 | 2.138577 |
bavituximab
|
kappa
|
XI
|
IgG1
|
Phase 3
| false | 2,006 | null |
EVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS
|
DIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK
|
kappa
|
WHO-INN
|
PL95
| null | null | 45.110274 | 59.5 | 0 | 11.499 | 12.689 | 0.0404 | 0.557037 | 29.851202 | 11.395 | -0.01 | 1.315456 | 1.692884 |
belimumab
|
lambda
|
HU
|
IgG1
|
Approved
| true | 2,003 | null |
QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSS
|
SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVL
|
lambda
|
US Patent
|
US8101181
| null | null | 10.472727 | 60 | 800 | 10.461 | 9.267 | 0.1304 | 0 | 0.771252 | 8.588 | -0.03 | 3.609535 | 12.228952 |
benralizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 2,009 | null |
EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVIHWVRQRPGQGLAWMGYINPYNDGTKYNERFKGKVTITSDRSTSTVYMELSSLRSEDTAVYLCGREGIRYYGLLGDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCGTSEDIINYLNWYQQKPGKAPKLLIYHTSRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGYTLPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL102
| null | null | 146.712684 | 76 | 800 | 9.467 | 9.09 | 0.0243 | 0.353712 | 5.977933 | 9.628 | -0.01 | 1.231263 | 1.424719 |
bevacizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,000 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
|
kappa
|
PDB
|
1BJ1
| null | null | 49.978578 | 63.5 | 700 | 11.772 | 11.07 | 0.2198 | 0 | 0.79022 | 9.822 | -0.02 | 1.285914 | 2.784692 |
bimagrumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true | 2,012 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS
|
QSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL108
| null | null | 150.238851 | 72 | 0 | 10.125 | 8.829 | 0.09126 | 0.696556 | 29.645095 | 12.328 | 0.1 | 1.548608 | 5.327787 |
blosozumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| true | 2,011 | null |
QVQLVQSGAEVKKPGASVKVSCKVSGFPIKDTFQHWVRQAPGKGLEWMGWSDPEIGDTEYASKFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCATGDTTYKFDFWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVHTAVAWYQQKPGKAPKLLIYWASTRWTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSDYPWTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 120.009752 | 70.5 | 600 | 9.241 | 8.626 | 0.1252 | 0.208243 | 11.472476 | 8.866 | 0.46 | 13.177765 | 12.84792 |
bococizumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| true | 2,013 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGEISPFGGRTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARERPLYASDLWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQRYSLWRTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 95.786921 | 67 | 0 | 10.179 | 9.108 | 0.067 | 0.760184 | 29.645095 | 10.595 | 0.5 | 13.496458 | 18.877205 |
brentuximab
|
kappa
|
XI
|
IgG1-ADC
|
Approved
| false | 2,010 | null |
QIQLQQSGPEVVKPGASVKISCKASGYTFTDYYITWVKQKPGQGLEWIGWIYPGSGNTKYNEKFKGKATLTVDTSSSTAFMQLSSLTSEDTAVYFCANYGNYWFAYWGQGTQVTVSA
|
DIVLTQSPASLAVSLGQRATISCKASQSVDFDGDSYMNWYQQKPGQPPKVLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 268.061982 | 72 | 800 | 10.535 | 8.683 | -0.003086 | 0.247488 | -0.542427 | 8.551 | -0.03 | 4.2116 | 2.242928 |
briakinumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true | 2,009 | null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAFIRYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCKTHGSHDNWGQGTMVTVSS
|
QSVLTQPPSVSGAPGQRVTISCSGSRSNIGSNTVKWYQQLPGTAPKLLIYYNDQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDRYTHPALLFGTGTKVTVL
|
lambda
|
WHO-INN
|
PL101
| null | null | 121.992234 | 71.5 | 0 | 9.359 | 8.737 | 0.1054 | 0.556059 | 29.645095 | 10.394 | 0.02 | 4.829996 | 10.217637 |
brodalumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false | 2,011 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTRYGISWVRQAPGQGLEWMGWISTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARRQLYFDYWGQGTLVTVSS
|
EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWFQQKPGQAPRPLIYDASTRATGVPARFSGSGSGTDFTLTISSLQSEDFAVYYCQQYDNWPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 150.862586 | 74.5 | 900 | 9.079 | 8.743 | 0.01717 | 0.26549 | 11.207609 | 8.971 | -0.01 | 1.475125 | 2.92579 |
canakinumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,007 | null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSS
|
EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIK
|
kappa
|
US Patent
|
US8105587
| null | null | 45.724929 | 72 | 800 | 9.321 | 8.727 | 0.03791 | 0 | 0.669938 | 8.635 | 0 | 1.195418 | 2.545757 |
carlumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| true | 2,010 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYGISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSDAYLAWYQQKPGQAPRLLIYDASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYIQLHSFTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 243.323478 | 69.5 | 700 | 11.167 | 9.31 | 0.07491 | 0.211582 | -0.438032 | 8.62 | -0.02 | 2.761083 | 8.879201 |
certolizumab
|
kappa
|
ZU
|
FabPEG
|
Approved
| false | 2,004 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIK
|
kappa
|
US Patent
|
US7402662
| null | null | 186.709369 | 81.5 | 500 | 11.478 | 10.815 | 0.04289 | 0 | 0.163095 | 9.314 | -0.01 | 1.143818 | 1.64792 |
cetuximab
|
kappa
|
XI
|
IgG1
|
Approved
| false | 1,999 | null |
QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSA
|
DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELK
|
kappa
|
PDB
|
1YY8
| null | null | 109.160445 | 68.5 | 400 | 10.11 | 8.91 | 0.05474 | 0 | 1.299961 | 8.906 | -0.04 | 1.09328 | 1.085524 |
cixutumumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true | 2,008 | null |
EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARAPLRFLEWSTQDHYYYYYMDVWGKGTTVTVSS
|
SSELTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPILVIYGENKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCKSRDGSGQHLVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL100
| null | null | 154.25963 | 73.5 | 0 | 11.76 | 10.723 | 0.1617 | 0.657024 | 29.645095 | 9.664 | 0.38 | 3.766344 | 11.90416 |
clazakizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,012 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFSLSNYYVTWVRQAPGKGLEWVGIIYGSDETAYATSAIGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDDSSDWDAKFNLWGQGTLVTVSS
|
AIQMTQSPSSLSASVGDRVTITCQASQSINNELSWYQQKPGKAPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQGYSLRNIDNAFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 113.477347 | 69.5 | 800 | 9.568 | 8.871 | 0.05306 | 0 | 0.930046 | 8.729 | -0.03 | 1.281554 | 4.115141 |
codrituzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,013 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPGQGLEWMGALDPKTGDTAYSQKFKGRVTLTADKSTSTAYMELSSLTSEDTAVYYCTRFYSYTYWGQGTLVTVSS
|
DVVMTQSPLSLPVTPGEPASISCRSSQSLVHSNRNTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQNTHVPPTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 66.347408 | 73 | 1,000 | 8.836 | 8.592 | 0.255 | 0.147987 | -0.285719 | 8.454 | -0.01 | 9.418865 | 14.874542 |
crenezumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 3
| false | 2,011 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMSWVRQAPGKGLELVASINSNGGSTYYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCASGDYWGQGTTVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSLVYSNGDTYLHWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 149.265977 | 72 | 700 | 10.031 | 8.703 | 0.04786 | 0.104936 | 6.3708 | 8.899 | 0 | 1.133396 | 2.780699 |
dacetuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,007 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGYYIHWVRQAPGKGLEWVARVIPNAGGTSYNQKFKGRFTLSVDNSKNTAYLQMNSLRAEDTAVYYCAREGIYWWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTFLHWYQQKPGKAPKLLIYTVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYFCSQTTHVPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL98
| null | null | 128.452216 | 68 | 1,000 | 8.466 | 8.614 | 0.0033 | 0 | -0.014676 | 8.467 | -0.04 | 1.079326 | 1.335206 |
daclizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 1,994 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS
|
DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK
|
kappa
|
PDB
|
3NFP
| null | null | 245.107923 | 74 | 900 | 9.286 | 8.751 | 0.02794 | 0 | -0.110586 | 8.476 | -0.02 | 1.180366 | 1.414309 |
dalotuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,009 | null |
QVQLQESGPGLVKPSETLSLTCTVSGYSITGGYLWNWIRQPPGKGLEWIGYISYDGTNNYKPSLKDRVTISRDTSKNQFSLKLSSVTAADTAVYYCARYGRVFFDYWGQGTLVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSIVHSNGNTYLQWYLQKPGQSPQLLIYKVSNRLYGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US7914784
|
Entries in WHO-INN documents (PL102 and RL64) have errors
| null | 82.41734 | 77 | 800 | 9.891 | 8.704 | 0.1466 | 0.399648 | 13.68059 | 9.118 | 0.14 | 2.898655 | 8.253577 |
daratumumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,009 | null |
EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 233.334298 | 71 | 800 | 9.514 | 8.926 | 0.06363 | 0 | 1.80923 | 8.855 | 0 | 1.213584 | 3.151414 |
denosumab
|
kappa
|
HU
|
IgG2
|
Approved
| false | 2,005 | null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US7364736
| null | null | 134.167846 | 69.5 | 1,000 | 8.501 | 8.603 | 0.01043 | 0 | 5.907925 | 8.811 | 0.11 | 5.917966 | 17.74975 |
dinutuximab
|
kappa
|
XI
|
IgG1
|
Approved
| false | 2,013 | null |
EVQLLQSGPELEKPGASVMISCKASGSSFTGYNMNWVRQNIGKSLEWIGAIDPYYGGTSYNQKFKGRATLTVDKSSSTAYMHLKSLTSEDSAVYYCVSGMEYWGQGTSVTVSS
|
EIVMTQSPATLSVSPGERATLSCRSSQSLVHRNGNTYLHWYLQKPGQSPKLLIHKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPPLTFGAGTKLELK
|
kappa
|
WHO-INN
|
PL109
| null | null | 76.42882 | 69 | 800 | 9.833 | 8.963 | 0.0098 | 0.302741 | 3.635206 | 9.405 | -0.02 | 1.030887 | 1.69176 |
drozitumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true | 2,010 | null |
EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS
|
SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL103
| null | null | 22.068896 | 63 | 0 | 9.29 | 8.716 | 0.02829 | 0 | 29.645095 | 8.79 | 0.04 | 1.096797 | 1.479534 |
duligotuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true | 2,012 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFTLSGDWIHWVRQAPGKGLEWVGEISAAGGYTDYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARESRVSFEAAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQNIATDVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSEPEPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 192.582804 | 67.5 | 0 | 10.206 | 8.938 | 0.05514 | 0.33444 | 29.645095 | 9.53 | 0.6 | 8.539748 | 9.630616 |
dupilumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 3
| false | 2,012 | null |
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTTVTVSS
|
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 163.549147 | 76.5 | 700 | 10.159 | 9.009 | 0.02874 | 0.146876 | 10.804212 | 9.752 | -0.01 | 8.694358 | 19.270549 |
eculizumab
|
kappa
|
ZU
|
IgG24
|
Approved
| false | 2,002 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYIFSNYWIQWVRQAPGQGLEWMGEILPGSGSTEYTENFKDRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARYFFGSSPNWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCGASENIYGALNWYQQKPGKAPKLLIYGATNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNVLNTPLTFGQGTKVEIK
|
kappa
|
US Patent
|
US6355245
| null | null | 226.468532 | 66 | 700 | 10.41 | 9.277 | 0.008 | 0 | 0.043333 | 8.499 | -0.04 | 0.959428 | 2.995506 |
efalizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,001 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHPSDSETRYNQKFKDRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARGIYFYGTTYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK
|
kappa
|
PDB
|
3EOA
| null | null | 166.992344 | 72.5 | 900 | 8.668 | 8.641 | 0 | 0 | 0.681276 | 8.542 | -0.02 | 0.98291 | 1.238202 |
eldelumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false | 2,013 | null |
QMQLVESGGGVVQPGRSLRLSCTASGFTFSNNGMHWVRQAPGKGLEWVAVIWFDGMNKFYVDSVKGRFTISRDNSKNTLYLEMNSLRAEDTAIYYCAREGDGSGIYYYYGMDVWGQGTTVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPIFTFGPGTKVDIK
|
kappa
|
WHO-INN
|
PL109
| null | null | 89.253053 | 59.5 | 500 | 12.422 | 25 | 0.0998 | 0 | 1.21252 | 10.156 | -0.02 | 1.109093 | 1.747088 |
elotuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,008 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 213.1906 | 83.5 | 700 | 10.314 | 9.288 | 0 | 0 | -0.224469 | 8.469 | -0.03 | 0.978042 | 1.264794 |
emibetuzumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| true | 2,014 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQVYSGYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 98.748918 | 71.5 | 0 | 9.638 | 8.684 | 0.04114 | 0.643143 | 29.645095 | 9.528 | 0.06 | 3.300083 | 8.329451 |
enokizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true | 2,010 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSYYWIEWVRQAPGQGLEWMGEILPGSGTTNPNEKFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARADYYGSDYVKFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKASQHVITHVTWYQQKPGKAPKLLIYGTSYSYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYEYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 239.819013 | 68 | 600 | 12.934 | 10.881 | 0.08966 | 0.125828 | 1.533553 | 9.028 | -0.02 | 1.173417 | 3.239268 |
epratuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 1,999 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIGYINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCARRDITTFYWGQGTTVTVSS
|
DIQLTQSPSSLSASVGDRVTMSCKSSQSVLYSANHKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYLSSWTFGGGTKLEIK
|
kappa
|
US Patent
|
US5789554
| null | null | 78.230572 | 65 | 900 | 9.189 | 8.629 | 0.02629 | 0.130915 | 3.014187 | 8.689 | -0.01 | 1.474552 | 2.342762 |
etrolizumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true | 2,010 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFFITNNYWGWVRQAPGKGLEWVGYISYSGSTSYNPSLKSRFTISRDTSKNTFYLQMNSLRAEDTAVYYCARTGSSGYFDFWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASESVDDLLHWYQQKPGKAPKLLIKYASQSISGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNSLPNTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 173.842456 | 76 | 900 | 9.322 | 8.77 | 0.2009 | 0.420378 | 2.017646 | 8.768 | -0.03 | 2.182071 | 4.228952 |
evolocumab
|
lambda
|
HU
|
IgG2
|
Approved
| false | 2,012 | null |
EVQLVQSGAEVKKPGASVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNGNTNYAQKLQGRGTMTTDPSTSTAYMELRSLRSDDTAVYYCARGYGMDVWGQGTTVTVSS
|
ESALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCNSYTSTSMVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL108
| null | null | 260.677128 | 65 | 700 | 10.355 | 9.13 | 0.0298 | 0.204333 | 2.236431 | 9.254 | -0.01 | 1.754453 | 1.754409 |
farletuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 2,008 | null |
EVQLVESGGGVVQPGRSLRLSCSASGFTFSGYGLSWVRQAPGKGLEWVAMISSGGSYTYYADSVKGRFAISRDNAKNTLFLQMDSLRPEDTGVYFCARHGDDPAWFAYWGQGTPVTVSS
|
DIQLTQSPSSLSASVGDRVTITCSVSSSISSNNLHWYQQKPGKAPKPWIYGTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSYPYMYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 220.817624 | 75.5 | 800 | 9.491 | 9.065 | 0.006029 | 0 | -0.501925 | 8.687 | -0.01 | 1.073797 | 1.321797 |
fasinumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 3
| false | 2,012 | null |
QVQLVQSGAEVKKPGASVKVSCKVSGFTLTELSIHWVRQAPGKGLEWMGGFDPEDGETIYAQKFQGRVTMTEDTSTDTAYMELTSLRSEDTAVYYCSTIFGVVTNFDNWGQGTLVTVSS
|
DIQMTQSPSSLSASAGDRVTITCRASQAIRNDLGWYQQKPGKAPKRLIYAAFNLQSGVPSRFSGSGSGTEFTLTISSLQPEDLASYYCQQYNRYPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 110.374487 | 71 | 900 | 10.026 | 8.715 | 0.06657 | 0 | -0.671927 | 8.359 | -0.02 | 1.156861 | 2.527121 |
fezakinumab
|
lambda
|
HU
|
IgG1
|
Phase 2
| true | 2,009 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWVGWINPYTGSAFYAQKFRGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAREPEKFDSDDSDVWGRGTLVTVSS
|
QAVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYGVHWYQQLPGTAPKLLIYGDSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDNSLSGYVFGGGTQLTVL
|
lambda
|
WHO-INN
|
PL101
| null | null | 141.453494 | 69 | 600 | 11.798 | 13.709 | 0.06932 | 0.264712 | 2.50184 | 11.26 | -0.0158 | 1.145613 | 2.146423 |
ficlatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,011 | null |
QVQLVQPGAEVKKPGTSVKLSCKASGYTFTTYWMHWVRQAPGQGLEWIGEINPTNGHTNYNQKFQGRATLTVDKSTSTAYMELSSLRSEDTAVYYCARNYVGSIFDYWGQGTLLTVSS
|
DIVMTQSPDSLAMSLGERVTLNCKASENVVSYVSWYQQKPGQSPKLLIYGASNRESGVPDRFSGSGSATDFTLTISSVQAEDVADYHCGQSYNYPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 249.025765 | 75 | 900 | 9.421 | 8.882 | 0.04614 | 0 | -0.893786 | 8.488 | -0.02 | 1.133884 | 1.233278 |
figitumumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false | 2,008 | null |
EVQLLESGGGLVQPGGSLRLSCTASGFTFSSYAMNWVRQAPGKGLEWVSAISGSGGTTFYADSVKGRFTISRDNSRTTLYLQMNSLRAEDTAVYYCAKDLGWSDSYYYYYGMDVWGQGTTVTVSS
|
DIQMTQFPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASRLHRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPCSFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 119.916768 | 66.5 | 0 | 10.745 | 9.86 | 0.06446 | 0.378958 | 29.645095 | 10.533 | 0.02 | 2.893762 | 5.650582 |
fletikumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 2
| false | 2,013 | null |
QVQLVQSGAEVKRPGASVKVSCKASGYTFTNDIIHWVRQAPGQRLEWMGWINAGYGNTQYSQNFQDRVSITRDTSASTAYMELISLRSEDTAVYYCAREPLWFGESSPHDYYGMDVWGQGTTVTVSS
|
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 220.376225 | 71.5 | 700 | 11.038 | 9.143 | 0.01897 | 0 | -0.125458 | 8.474 | -0.02 | 1.024451 | 1.408319 |
foralumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false | 2,010 | null |
QVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 174.435088 | 66 | 0 | 9.842 | 8.574 | 0.03766 | 0.371715 | 28.085284 | 9.324 | 0 | 4.767634 | 4.711481 |
fresolimumab
|
kappa
|
HU
|
IgG4
|
Phase 2
| true | 2,009 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCASTLGLVLDAMDYWGQGTLVTVSS
|
ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 166.036557 | 74 | 700 | 10.875 | 9.145 | 0.05526 | 0 | -0.515083 | 8.466 | -0.02 | 1.300181 | 3.512812 |
fulranumab
|
kappa
|
HU
|
IgG2
|
Phase 3
| false | 2,010 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFTLRSYSMNWVRQAPGKGLEWVSYISRSSHTIFYADSVKGRFTISRDNAKNSLYLQMDSLRDEDTAMYYCARVYSSGWHVSDYFDYWGQGILVTVSS
|
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 142.018924 | 68.5 | 900 | 9.328 | 9.342 | 0.07229 | 0.187679 | 11.560721 | 9.346 | 0 | 1.849308 | 6.923128 |
galiximab
|
lambda
|
XI
|
IgG1
|
Phase 2
| false | 2,003 | null |
QVQLQESGPGLVKPSETLSLTCAVSGGSISGGYGWGWIRQPPGKGLEWIGSFYSSSGNTYYNPSLKSQVTISTDTSKNQFSLKLNSMTAADTAVYYCVRDRLFSVVGMVYNNWFDVWGPGVLVTVSS
|
ESALTQPPSVSGAPGQKVTISCTGSTSNIGGYDLHWYQQLPGTAPKLLIYDINKRPSGISDRFSGSKSGTAASLAITGLQTEDEADYYCQSYDSSLNAQVFGGGTRLTVL
|
lambda
|
US Patent
|
US6113898
| null | null | 174.116872 | 67.5 | 600 | 12.198 | 14.77 | 0.03135 | 0 | 1.093714 | 8.87 | -0.02 | 1.213663 | 3.810316 |
ganitumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| true | 2,010 | null |
QVQLQESGPGLVKPSGTLSLTCAVSGGSISSSNWWSWVRQPPGKGLEWIGEIYHSGSTNYNPSLKSRVTISVDKSKNQFSLKLSSVTAADTAVYYCARWTGRTDAFDIWGQGTMVTVSS
|
DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 229.43987 | 78.5 | 800 | 9.334 | 8.77 | 0.01174 | 0.552845 | 4.774833 | 9.482 | -0.01 | 1.295156 | 4.907155 |
gantenerumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| true | 2,007 | null |
QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGTRTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRYFDVWGQGTLVTVSS
|
DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL97
| null | null | 162.659011 | 77.5 | 1,000 | 9.004 | 8.487 | 0.06671 | 0.5526 | 6.957989 | 8.709 | 0.1 | 13.82019 | 22.74609 |
gemtuzumab
|
kappa
|
ZU
|
IgG4-ADC
|
Approved
| false | 2,000 | null |
EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS
|
DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQKPGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQTKEVPWSFGQGTKVEVK
|
kappa
|
US Patent
|
US5773001
| null | null | 171.299785 | 72.5 | 500 | 12.259 | 13.931 | 0.04534 | 0 | 1.020051 | 9.106 | -0.01 | 1.080084 | 1.697837 |
gevokizumab
|
kappa
|
ZU
|
IgG2
|
Phase 3
| false | 2,010 | null |
QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS
|
DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 136.360641 | 71.5 | 1,000 | 8.828 | 8.607 | 0.07129 | 0 | -0.51477 | 8.579 | -0.03 | 1.18008 | 1.931448 |
girentuximab
|
kappa
|
XI
|
IgG1
|
Phase 3
| false | 2,009 | null |
DVKLVESGGGLVKLGGSLKLSCAASGFTFSNYYMSWVRQTPEKRLELVAAINSDGGITYYLDTVKGRFTISRDNAKNTLYLQMSSLKSEDTALFYCARHRSGYFSMDYWGQGTSVTVSS
|
DIVMTQSQRFMSTTVGDRVSITCKASQNVVSAVAWYQQKPGQSPKLLIYSASNRYTGVPDRFTGSGSGTDFTLTISNMQSEDLADFFCQQYSNYPWTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 30.72183 | 63 | 1,000 | 9.081 | 8.683 | 0.03154 | 0 | -0.751821 | 8.524 | -0.04 | 1.090143 | 1.393677 |
glembatumumab
|
kappa
|
HU
|
IgG2
|
Phase 2
| false | 2,009 | null |
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS
|
EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL102
| null | null | 152.712345 | 70.5 | 0 | 13.68 | 25 | 0.303 | 0.166107 | 28.880635 | 13.5 | 0.01 | 1.063291 | 2.215356 |
golimumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,004 | null |
QVQLVESGGGVVQPGRSLRLSCAASGFIFSSYAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGIAAGGNYYYYGMDVWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVYSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPFTFGPGTKVDIK
|
kappa
|
US Patent
|
US7250165
| null | null | 163.238323 | 70 | 0 | 11.359 | 12.747 | 0.06274 | 0.234008 | 22.965397 | 11.23 | -0.01 | 1.309296 | 2.712146 |
guselkumab
|
lambda
|
HU
|
IgG1
|
Phase 3
| true | 2,013 | null |
EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
|
QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL109
| null | null | 167.340129 | 69.5 | 700 | 11.403 | 9.195 | 0.1931 | 0.469339 | 3.367196 | 10.109 | 0.02 | 1.541176 | 5.867554 |
ibalizumab
|
kappa
|
ZU
|
IgG4
|
Phase 3
| false | 2,007 | null |
QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS
|
DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIK
|
kappa
|
WHO-INN
|
PL97
| null | null | 133.282633 | 72 | 800 | 10.237 | 9.771 | 0.0393 | 0 | -0.339304 | 8.66 | -0.03 | 0.993142 | 1.126217 |
imgatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,012 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGFTFTDYKIHWVRQAPGQGLEWMGYFNPNSGYSTYAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARLSPGGYYVMDAWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQGINNYLNWYQQKPGKAPKRLIYNTNNLQTGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 187.708497 | 71.5 | 800 | 10.09 | 8.898 | 0.06543 | 0 | 0.893874 | 8.994 | -0.01 | 5.014941 | 11.774376 |
infliximab
|
kappa
|
XI
|
IgG1
|
Approved
| false | 1,997 | null |
EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS
|
DILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK
|
kappa
|
PDB
|
4G3Y
| null | null | 6.581146 | 64.5 | 0 | 10.36 | 8.888 | 0.1812 | 0 | 29.645095 | 9.011 | 0.05 | 1.036832 | 1.371714 |
inotuzumab
|
kappa
|
ZU
|
IgG4-ADC
|
Phase 3
| false | 2,004 | null |
EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS
|
DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK
|
kappa
|
US Patent
|
US7355011
| null | null | 169.767062 | 83 | 800 | 9.717 | 9.052 | 0.02517 | 0.250008 | 4.029671 | 9.295 | 0.01 | 3.180205 | 5.395674 |
ipilimumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,005 | null |
QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
|
EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US6984720
| null | null | 169.561868 | 73 | 400 | 11.57 | 12.981 | 0.03963 | 0.229631 | 10.413099 | 10.941 | 0.01 | 1.052425 | 1.691847 |
ixekizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Approved
| true | 2,011 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSS
|
DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL105
| null | null | 97.277433 | 83 | 500 | 10.936 | 9.082 | 0.1614 | 0.809817 | 19.952343 | 9.636 | 0.11 | 8.79746 | 10.398669 |
lampalizumab
|
kappa
|
ZU
|
Fab
|
Phase 3
| false | 2,012 | null |
EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSS
|
DIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNTLRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 187.075402 | 67 | 800 | 9.25 | 8.765 | 0.08749 | 0 | 0.494177 | 8.455 | -0.03 | 1.108848 | 1.340433 |
lebrikizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 3
| false | 2,009 | null |
QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
|
DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL101
| null | null | 61.607125 | 66 | 500 | 12.381 | 15.71 | 0.0047 | 0 | 0.255326 | 9.071 | -0.04 | 0.962254 | 1.45618 |
lenzilumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| true | 2,014 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
|
EIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL111
| null | null | 184.742758 | 74 | 0 | 8.722 | 8.605 | 0.03277 | 0.655128 | 29.645095 | 10.122 | 0.02 | 14.459031 | 19.604659 |
lintuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 1,996 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYTFTDYNMHWVRQAPGQGLEWIGYIYPYNGGTGYNQKFKSKATITADESTNTAYMELSSLRSEDTAVYYCARGRPAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASESVDNYGISFMNWFQQKPGKAPKLLIYAASNQGSGVPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQSKEVPWTFGQGTKVEIK
|
kappa
|
US Patent
|
US5530101
| null | null | 229.970848 | 75.5 | 700 | 10.874 | 9.428 | 0.048 | 0 | 0.885988 | 8.933 | -0.02 | 1.045706 | 1.254576 |
lirilumab
|
kappa
|
HU
|
IgG4-CPPC
|
Phase 2
| false | 2,012 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSFYAISWVRQAPGQGLEWMGGFIPIFGAANYAQKFQGRVTITADESTSTAYMELSSLRSDDTAVYYCARIPSGSYYYDYDMDVWGQGTTVTVSS
|
EIVLTQSPVTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWMYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 270.480297 | 70 | 300 | 25 | 25 | 0.00174 | 0.182914 | 20.998948 | 10.562 | 0.04 | 1.269556 | 3.549418 |
lumiliximab
|
kappa
|
XI
|
IgG1
|
Phase 2
| false | 2,004 | null |
EVQLVESGGGLAKPGGSLRLSCAASGFRFTFNNYYMDWVRQAPGQGLEWVSRISSSGDPTWYADSVKGRFTISRENANNTLFLQMNSLRAEDTAVYYCASLTTGSDSWGQGVLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASQDIRYYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTEFTLTVSSLQPEDFATYYCLQVYSTPRTFGQGTKVEIK
|
kappa
|
US Patent
|
US6893636
| null | null | 86.273039 | 64.5 | 800 | 9.545 | 8.782 | 0.06686 | 0.144897 | 1.443549 | 8.815 | -0.02 | 1.137911 | 2.218303 |
matuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,003 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGLEWIGEFNPSNGRTNYNEKFKSKATMTVDTSTNTAYMELSSLRSEDTAVYYCASRDYDYDGRYFDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCSASSSVTYMYWYQQKPGKAPKLLIYDTSNLASGVPSRFSGSGSGTDYTFTISSLQPEDIATYYCQQWSSHIFTFGQGTKVEIK
|
kappa
|
PDB
|
3C08
| null | null | 224.328821 | 72 | 900 | 9.84 | 8.834 | 0.0164 | 0 | -0.927208 | 8.635 | -0.03 | 1.059855 | 1.027621 |
mavrilimumab
|
lambda
|
HU
|
IgG4
|
Phase 2
| true | 2,009 | null |
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS
|
QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL102
| null | null | 150.548853 | 68.5 | 700 | 10.296 | 8.671 | 0.04903 | 0 | -0.778754 | 8.496 | -0.01 | 1.213082 | 2.16173 |
mepolizumab
|
kappa
|
ZU
|
IgG1AA-mut
|
Approved
| false | 1,999 | null |
QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS
|
DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK
|
kappa
|
US Patent
|
US5693323
| null | null | 221.475177 | 78.5 | 900 | 9.238 | 8.816 | 0.04451 | 0 | -0.956637 | 8.408 | -0.04 | 1.131191 | 1.051581 |
mogamulizumab
|
kappa
|
ZU
|
IgG1-glyco
|
Approved
| false | 2,010 | null |
EVQLVESGGDLVQPGRSLRLSCAASGFIFSNYGMSWVRQAPGKGLEWVATISSASTYSYYPDSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYYCGRHSDGNFAFGYWGQGTLVTVSS
|
DVLMTQSPLSLPVTPGEPASISCRSSRNIVHINGDTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSLLPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 89.767929 | 68.5 | 800 | 9.641 | 8.82 | 0.03631 | 0 | -0.511762 | 8.631 | -0.02 | 1.118282 | 2.165724 |
motavizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| true | 2,006 | null |
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTAGMSVGWIRQPPGKALEWLADIWWDDKKHYNPSLKDRLTISKDTSKNQVVLKVTNMDPADTATYYCARDMIFNFYFDVWGQGTTVTVSS
|
DIQMTQSPSTLSASVGDRVTITCSASSRVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKVEIK
|
kappa
|
PDB
|
3IXT
| null | null | 133.551595 | 86 | 800 | 9.689 | 8.82 | 0.04454 | 0 | 2.522763 | 8.66 | -0.01 | 1.22954 | 5.360399 |
muromonab
|
kappa
|
XIa
|
IgG2a
|
Approved
| false | 1,988 | null |
QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
|
QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIK
|
kappa
|
PDB
|
1SY6
|
Last residue of LC variable region changed from N to K. N would create a NRT N-glycosylation site when joined to human CK sequence
| null | 113.52288 | 74.5 | 1,000 | 8.899 | 8.578 | 0.03829 | 0.175892 | 2.311513 | 9.048 | 0.01 | 1.408897 | 3.937438 |
natalizumab
|
kappa
|
ZU
|
IgG4
|
Approved
| false | 1,998 | null |
QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIK
|
kappa
|
US Patent
|
US5840299
| null | null | 251.745705 | 79.5 | 900 | 9.7 | 8.843 | 0.01877 | 0 | 0.822884 | 8.764 | -0.01 | 1.063994 | 1.524792 |
necitumumab
|
kappa
|
HU
|
IgG1
|
Approved
| true | 2,008 | null |
QVQLQESGPGLVKPSQTLSLTCTVSGGSISSGDYYWSWIRQPPGKGLEWIGYIYYSGSTDYNPSLKSRVTMSVDTSKNQFSLKVNSVTAADTAVYYCARVSIFGVGTFDYWGQGTLVTVSS
|
EIVMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSTPLTFGGGTKAEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 198.599891 | 76.5 | 600 | 10.807 | 9.9 | 0.0204 | 0 | 1.300578 | 8.771 | -0.02 | 1.045456 | 1.310483 |
nimotuzumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,005 | null |
QVQLQQSGAEVKKPGSSVKVSCKASGYTFTNYYIYWVRQAPGQGLEWIGGINPTSGGSNFNEKFKTRVTITADESSTTAYMELSSLRSEDTAFYFCTRQGLWFDSDGRGFDFWGQGTTVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRSSQNIVHSNGNTYLDWYQQTPGKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCFQYSHVPWTFGQGTKLQIT
|
kappa
|
PDB
|
3GKW
| null | null | 15.13165 | 65.5 | 900 | 25 | 8.884 | 0.04357 | 0 | -0.585505 | 8.464 | -0.02 | 1.318679 | 3.424293 |
nivolumab
|
kappa
|
HU
|
IgG4-CPPC
|
Approved
| false | 2,012 | null |
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 178.809229 | 66 | 900 | 9.023 | 8.655 | 0.02743 | 0.135175 | 2.41804 | 8.853 | -0.01 | 1.153877 | 1.324459 |
obinutuzumab
|
kappa
|
ZU
|
IgG1-glyco
|
Approved
| false | 2,009 | null |
QVQLVQSGAEVKKPGSSVKVSCKASGYAFSYSWINWVRQAPGQGLEWMGRIFPGDGDTDYNGKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARNVFDGYWLVYWGQGTLVTVSS
|
DIVMTQTPLSLPVTPGEPASISCRSSKSLLHSNGITYLYWYLQKPGQSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCAQNLELPYTFGGGTKVEIK
|
kappa
|
WHO-INN
|
RL65
| null | null | 176.441448 | 73 | 600 | 10.641 | 8.964 | 0.0128 | 0.112785 | 1.831573 | 8.8 | -0.01 | 0.950558 | 1.629588 |
ocrelizumab
|
kappa
|
ZU
|
IgG1
|
Phase 3
| false | 2,005 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYNMHWVRQAPGKGLEWVGAIYPGNGDTSYNQKFKGRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARVVYYSNSYWYFDVWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRASSSVSYMHWYQQKPGKAPKPLIYAPSNLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQWSFNPPTFGQGTKVEIK
|
kappa
|
US Patent
|
US8562992
| null | null | 137.774414 | 70.5 | 300 | 9.911 | 8.83 | 0.0237 | 0 | 17.881994 | 9.532 | 0.01 | 1.128492 | 1.672659 |
ofatumumab
|
kappa
|
HU
|
IgG1
|
Approved
| false | 2,005 | null |
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK
|
kappa
|
PDB
|
3GIZ
| null | null | 249.752167 | 68 | 800 | 9.729 | 9.524 | 0.02874 | 0 | 1.209699 | 9.248 | -0.02 | 1.122143 | 1.176705 |
olaratumab
|
kappa
|
HU
|
IgG1
|
Phase 2
| false | 2,010 | null |
QLQLQESGPGLVKPSETLSLTCTVSGGSINSSSYYWGWLRQSPGKGLEWIGSFFYTGSTYYNPSLRSRLTISVDTSKNQFSLMLSSVTAADTAVYYCARQSTYYYGSGNYYGWFDRWDQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPAFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 141.936048 | 62.5 | 700 | 10.609 | 8.957 | 0.2885 | 0.483143 | 0.310395 | 9.417 | -0.02 | 1.316067 | 2.584359 |
olokizumab
|
kappa
|
ZU
|
IgG4-CPPC
|
Phase 2
| false | 2,010 | null |
EVQLVESGGGLVQPGGSLRLSCAASGFNFNDYFMNWVRQAPGKGLEWVAQMRNKNYQYGTYYAESLEGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARESYYGFTSYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCQASQDIGISLSWYQQKPGKAPKLLIYNANNLADGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSAPYTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL103
| null | null | 115.258271 | 69 | 700 | 9.908 | 8.973 | 0.04469 | 0 | -0.502615 | 8.749 | -0.03 | 1.105369 | 1.229285 |
omalizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 2,000 | null |
EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSLKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
|
DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
|
kappa
|
PDB
|
2XA8
|
CDR-H2 has V to L mutation (unintended)
| null | 150.447109 | 77.5 | 800 | 9.519 | 8.744 | 0.04511 | 0 | -0.438278 | 8.538 | -0.02 | 1.116105 | 1.166057 |
onartuzumab
|
kappa
|
ZU
|
IgG1-One-armed
|
Phase 3
| false | 2,010 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPSNSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL104
| null | null | 147.933138 | 80 | 800 | 9.919 | 8.869 | 0.04311 | 0 | -0.046662 | 8.911 | -0.02 | 1.119281 | 1.186689 |
otelixizumab
|
lambda
|
XIZUb
|
IgG1-no-glyco
|
Phase 3
| false | 2,007 | null |
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFPMAWVRQAPGKGLEWVSTISTSGGRTYYRDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKFRQYSGGFDYWGQGTLVTVSS
|
DIQLTQPNSVSTSLGSTVKLSCTLSSGNIENNYVHWYQLYEGRSPTTMIYDDDKRPDGVPDRFSGSIDRSSNSAFLTIHNVAIEDEAIYFCHSYVSSFNVFGGGTKLTVL
|
lambda
|
WHO-INN
|
PL98
| null | null | 152.082453 | 75.5 | 1,000 | 9.082 | 8.72 | 0.08814 | 0 | 4.438287 | 8.719 | -0.02 | 1.127822 | 1.397671 |
otlertuzumab
|
kappa
|
ZU
|
scFv-Fc
|
Phase 2
| false | 2,013 | null |
EVQLVQSGAEVKKPGESLKISCKGSGYSFTGYNMNWVRQMPGKGLEWMGNIDPYYGGTTYNRKFKGQVTISADKSISTAYLQWSSLKASDTAMYYCARSVGPFDSWGQGTLVTVSS
|
EIVLTQSPATLSLSPGERATLSCRASENVYSYLAWYQQKPGQAPRLLIYFAKTLAEGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHHSDNPWTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL110
| null | null | 149.600654 | 68.5 | 600 | 10.959 | 10.267 | 0.07229 | 0 | 2.260983 | 9.516 | -0.03 | 1.171753 | 1.781697 |
ozanezumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| false | 2,012 | null |
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQGLEWIGNINPSNGGTNYNEKFKSKATMTRDTSTSTAYMELSSLRSEDTAVYYCELMQGYWGQGTLVTVSS
|
DIVMTQSPLSNPVTLGQPVSISCRSSKSLLYKDGKTYLNWFLQRPGQSPQLLIYLMSTRASGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCQQLVEYPLTFGQGTKLEIK
|
kappa
|
WHO-INN
|
PL108
| null | null | 97.074688 | 67 | 0 | 10.034 | 8.632 | 0.05569 | 0.771314 | 27.692332 | 9.046 | 0.45 | 2.029358 | 4.452579 |
palivizumab
|
kappa
|
ZU
|
IgG1
|
Approved
| false | 1,998 | null |
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS
|
DIQMTQSPSTLSASVGDRVTITCKCQLSVGYMHWYQQKPGKAPKLLIYDTSKLASGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCFQGSGYPFTFGGGTKLEIK
|
kappa
|
US Patent
|
US7704505
| null | null | 243.119698 | 79.5 | 900 | 9.332 | 8.705 | 0.03666 | 0 | -0.852685 | 8.491 | -0.03 | 1.118847 | 2.876539 |
panitumumab
|
kappa
|
HU
|
IgG2
|
Approved
| false | 2,004 | null |
QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGDYYWTWIRQSPGKGLEWIGHIYYSGNTNYNPSLKSRLTISIDTSKTQFSLKLSSVTAADTAIYYCVRDRVTGAFDIWGQGTMVTVSS
|
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYFCQHFDHLPLAFGGGTKVEIK
|
kappa
|
US Patent
|
US8628773
| null | null | 179.587857 | 78.5 | 900 | 9.479 | 8.799 | 0.03631 | 0 | -1.084605 | 8.42 | -0.03 | 1.062088 | 1.182696 |
panobacumab
|
kappa
|
HU
|
IgM
|
Phase 2
| false | 2,008 | null |
EEQVVESGGGFVQPGGSLRLSCAASGFTFSPYWMHWVRQAPGKGLVWVSRINSDGSTYYADSVKGRFTISRDNARNTLYLQMNSLRAEDTAVYYCARDRYYGPEMWGQGTMVTVSS
|
DVVMTQSPLSLPVTLGQPASISCRSSQSLVYSDGNTYLNWFQQRPGQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPLTFGGGTKVEIK
|
kappa
|
WHO-INN
|
PL100
| null | null | 107.597686 | 69 | 900 | 9.827 | 8.85 | 0.02071 | 0 | -0.415577 | 8.992 | -0.01 | 1.212667 | 1.896839 |
parsatuzumab
|
kappa
|
ZU
|
IgG1
|
Phase 2
| true | 2,012 | null |
EVQLVESGGGLVQPGGSLRLSCAASGYTFIDYYMNWVRQAPGKGLEWVGDINLDNSGTHYNQKFKGRFTISRDKSKNTAYLQMNSLRAEDTAVYYCAREGVYHDYDDYAMDYWGQGTLVTVSS
|
DIQMTQSPSSLSASVGDRVTITCRTSQSLVHINAITYLHWYQQKPGKAPKLLIYRVSNRFSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSTHVPLTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL107
| null | null | 40.019327 | 64.5 | 900 | 9.109 | 8.781 | 0.08654 | 0.134444 | 7.400359 | 8.651 | 0.12 | 10.046527 | 17.395674 |
patritumab
|
kappa
|
HU
|
IgG1
|
Phase 3
| false | 2,011 | null |
QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS
|
DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK
|
kappa
|
WHO-INN
|
PL106
| null | null | 68.77442 | 71.5 | 600 | 10.15 | 9.321 | 0.05371 | 0.520073 | 13.086408 | 9.445 | 0.04 | 2.346217 | 4.34609 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.